Population
Patients with congenital myopathies (including central core myopathy and centronuclear/myotubular myopathy)
Design
Review
Authors
Loading...
Should not yet alter congenital myopathy management; extends classification but leaves therapeutic implications open.
Advances in immunohistochemistry and molecular genetics are expanding the understanding and classification of congenital myopathies.
John B. Bodensteiner (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: